Form 8-K - Current report:
SEC Accession No. 0001193125-23-086922
Filing Date
2023-03-31
Accepted
2023-03-31 08:57:29
Documents
14
Period of Report
2023-03-27
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d477438d8k.htm   iXBRL 8-K 32119
2 EX-99.1 d477438dex991.htm EX-99.1 16384
6 GRAPHIC g477438g0331083133199.jpg GRAPHIC 3015
  Complete submission text file 0001193125-23-086922.txt   183753

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tcrx-20230327.xsd EX-101.SCH 2844
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tcrx-20230327_lab.xml EX-101.LAB 17978
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tcrx-20230327_pre.xml EX-101.PRE 11254
8 EXTRACTED XBRL INSTANCE DOCUMENT d477438d8k_htm.xml XML 3351
Mailing Address 880 WINTER STREET WALTHAM MA 02451
Business Address 880 WINTER STREET WALTHAM MA 02451 857-399-9500
TScan Therapeutics, Inc. (Filer) CIK: 0001783328 (see all company filings)

EIN.: 825282075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40603 | Film No.: 23783518
SIC: 2836 Biological Products, (No Diagnostic Substances)